WINRHO SDF 15000 UNIT
ANTI-D (RH) IMMUNOGLOBULIN (HUMAN) : 15000 UNIT · DIN 02302608 · KI BIOPHARMA LLC
Health Canada status: APPROVED
What is WINRHO SDF?
WINRHO SDF 15000 UNIT contains ANTI-D (RH) IMMUNOGLOBULIN (HUMAN) : 15000 UNIT. It is listed in the Health Canada Drug Product Database under DIN 02302608, held by KI BIOPHARMA LLC, supplied as SOLUTION for INTRAMUSCULAR ; INTRAVENOUS administration. Health Canada currently lists it as approved, status dated 27-Jun-2022. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
What is WINRHO SDF used for?
WinRho SDF, Rh o (D) Immunoglobulin (Human) is indicated for the prevention of Rh immunization in Rho (D) negative mothers not previously sensitized to the Rho (D) factor. WinRho SDF is recommended for prevention of Rh immunization of Rh o (D) negative women at risk of developing Rh antibodies. Rh o (D) Immunoglobulin (Human) prevents the development of Rh antibodies in the Rho (D) negative and previously not sensitized mother carrying a Rho (D) positive fetus, thus preventing the occu rrence of hemol ytic disease in the fetus or the newborn. WinRho SDF is recommended to prevent alloimmunization in Rh o (D) negative female children and female adults in their child - bearing years transfused with Rh o (D) positive RBCs or blood components with Rh o (D) positive RBCs. WinRho SDF is recommended in the treatment of destructive thrombocytopenia of an immune etiology in situations where platelet counts must be increased to control bleeding. WinRho SDF is recommended in clinical situations requiring an increase in platelet count to prevent excessive hemorrhage for the treatment of non - splenectomized Rh o (D) positive 1) children with chronic or acute ITP, 2) adults with chronic ITP, or 3) chi ldren and ad ults with ITP secondary to HIV infection.
Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.
Product details and regulatory record
| DIN | 02302608 |
|---|---|
| Brand name | WINRHO SDF |
| Generic / active ingredient | ANTI-D (RH) IMMUNOGLOBULIN (HUMAN) : 15000 UNIT |
| Manufacturer | KI BIOPHARMA LLC |
| Strength | 15000 UNIT |
| Dosage form | SOLUTION |
| Route of administration | INTRAMUSCULAR ; INTRAVENOUS |
| Schedule | Schedule D |
| ATC code | J06BB01 ANTI-D (RH) IMMUNOGLOBULIN |
| AHFS class | 28:08.04.92 |
| Biosimilar | No |
| Health Canada status | APPROVED |
| Status date | 27-Jun-2022 |
| Original market date | 2008-05-12 00:00:00 |
How is it stored and handled?
STORAGE AND STABILITY
How is it supplied?
Single-Dose Vials: 600 international units (120 mcg), 1,500 international units (300 mcg), 2,500 international units (500 mcg), 5,000 international units (1,000 mcg), 15,000 international units (3,000 mcg)
What can be used instead?
Other Canadian products sharing ATC code J06BB01 ANTI-D (RH) IMMUNOGLOBULIN. 2 of 11 DINs in this group are currently marketed — marketed products are listed first, because that is what can actually be bought. These tables describe supply, not clinical equivalence: substitution rests with the prescriber or pharmacist, and interchangeability is determined provincially.
| Product | Strength | Form | Manufacturer | Health Canada status | DIN |
|---|---|---|---|---|---|
| WINRHO SDF | 1500 UNIT | SOLUTION | KI BIOPHARMA LLC | MARKETED | DIN 02302578 |
| WINRHO SDF | 600 UNIT | SOLUTION | KI BIOPHARMA LLC | MARKETED | DIN 02302551 |
| HYP RHO D INJ 16.5% | 16.5 % | LIQUID | CUTTER MED & BIOL, DIVISION OF MILES CANADA LTD. | CANCELLED POST MARKET | DIN 00083267 |
| WINRHO SD KIT INJ | 120 MCG | KIT | RH PHARMACEUTICALS INC. | CANCELLED POST MARKET | DIN 02022842 |
| WINRHO SD KIT INJ. | .9 % | KIT | RH PHARMACEUTICALS INC. | CANCELLED POST MARKET | DIN 02022834 |
| WINRHO SDF | 1500 UNIT | KIT | APTEVO BIOTHERAPEUTICS LLC | CANCELLED POST MARKET | DIN 02217449 |
| WINRHO SDF | 2500 UNIT | SOLUTION | KI BIOPHARMA LLC | APPROVED | DIN 02302586 |
| WINRHO SDF | 5000 UNIT | SOLUTION | KI BIOPHARMA LLC | DORMANT | DIN 02302594 |
| WINRHO SDF | 5000 UNIT | KIT | APTEVO BIOTHERAPEUTICS LLC | CANCELLED POST MARKET | DIN 02230397 |
| WINRHO SDF | 600 UNIT | KIT | APTEVO BIOTHERAPEUTICS LLC | CANCELLED POST MARKET | DIN 02217430 |
Who else supplies ANTI-D (RH) IMMUNOGLOBULIN worldwide?
Nexara tracks national medicine registries and published price lists across multiple markets. ANTI-D (RH) IMMUNOGLOBULIN appears in 7 registered pack listings across 6 markets, published on 6 different national price bases. Where a Canadian route is closed, that is where an alternative route of supply starts — subject to the import rules in both countries.
Registered listings are not stock. Ask us to confirm what can actually be sourced for your order.
How can I get it?
Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.